pegfilgrastim


Also found in: Medical, Wikipedia.

peg·fil·gras·tim

 (pĕg′fĭl-grăs′tĭm)
n.
A preparation of the recombinant granulocyte colony-stimulating factor filgrastim conjugated with polyethylene glycol, used as a drug to treat neutropenia resulting from chemotherapy.

Translations

pegfilgrastim

n pegfilgrastim m
Mentioned in ?
References in periodicals archive ?
Sandoz, a Novartis company and global leader in biosimilars, today announced results from the PROTECT 2 study which compared the safety and efficacy of proposed biosimilar pegfilgrastim with the reference product, Neulasta.
Results from PROTECT 2, from Sandoz, investigating use of proposed biosimilar pegfilgrastim in patients with chemotherapy-induced neutropenia
12, 34-37) This involves in-depth immune profile blood testing and when indicated, precise administration of expensive drugs like interleukin-2, (12,38-46) filgrastim (Neupogen[R]), (47,48) pegfilgrastim (Neulasta[R]), (49-58) and/or sargramostim (Leukine[R]).
Patients with febrile neutropenia given prophylactic filgrastim or sargramostim should continue with G-CSF therapy; however, as pegfilgrastim is long acting patients given prophylactic pegfilgrastim should not be treated with additional G-CSF (66).
Introduction: Pegfilgrastim is administered in multiple clinical settings.
Your doctor should also prescribe medications such as filgrastim (Neupogen), pegfilgrastim (Neulasta) or sargramostim (Leukine) between chemotherapy cycles to quickly restore reduced white blood cell counts to normal levels to help prevent infection.
When needed, new-line growth factors such as pegfilgrastim (a form of recombinant granulocyte colony-stimulating factor) are expensive, with the upper limit of Medicare reimbursement totaling $2,508 a cycle (based on January 2004 CMS data).
Leukine is similar to Roche's filgrastim and pegfilgrastim, the two drugs Amgen purchased that fight the immune-suppressing effects of cancer treatment.
On 3 September, 2015 Sandoz launched the first biosimilar in the United States and recently had its regulatory submissions for biosimilar etanercept and biosimilar pegfilgrastim accepted by the FDA.
Do not administer Neulasta to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.
Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.